# Aciclovir Versus Placebo for HSV-2 Meningitis

> **NCT05452928** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Jacob Bodilsen** · enrollment: 150 (estimated)

## Conditions studied

- Herpes Simplex 2
- Meningitis, Viral

## Interventions

- **DRUG:** Acyclovir 50 MG/ML
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05452928
- **Lead sponsor:** Jacob Bodilsen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05452928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05452928, "Aciclovir Versus Placebo for HSV-2 Meningitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05452928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*